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Abstract
Background: Reactivation of Epstein-Barr virus (EBV) infection may cause serious, life-threatening complications in
immunocompromised individuals. EBV DNA is often detected in EBV-associated disease states, with viral load
believed to be a reflection of virus activity. Two separate real-time quantitative polymerase chain reaction (QPCR)
assays using SYBR Green I dye and a single quantification standard containing two EBV genes, Epstein-Barr nuclear
antigen-1 (EBNA-1) and BamHI fragment H rightward open reading frame-1 (BHRF-1), were developed to detect
and measure absolute EBV DNA load in patients with various EBV-associated diseases. EBV DNA loads and viral
capsid antigen (VCA) IgG antibody titres were also quantified on a population sample.
Results: EBV DNA was measurable in ethylenediaminetetraacetic acid (EDTA) whole blood, peripheral blood
mononuclear cells (PBMCs), plasma and cerebrospinal fluid (CSF) samples. EBV DNA loads were detectable from 8.0 × 10
2
to 1.3 × 10
8 copies/ml in post-transplant lymphoproliferative disease (n = 5), 1.5 × 10
3 to 2.0 × 10
5 copies/ml in
infectious mononucleosis (n = 7), 7.5 × 10
4 to 1.1 × 10
5 copies/ml in EBV-associated haemophagocytic syndrome (n = 1),
2.0 × 10
2 to 5.6 × 10
3 copies/ml in HIV-infected patients (n = 12), and 2.0 × 10
2 to 9.1 × 10
4 copies/ml in the population
sample (n = 218). EBNA-1 and BHRF-1 DNA were detected in 11.0% and 21.6% of the population sample respectively.
There was a modest correlation between VCA IgG antibody titre and BHRF-1 DNA load (rho = 0.13, p = 0.05) but not
EBNA-1 DNA load (rho = 0.11, p = 0.11).
Conclusion: Two sensitive and specific real-time PCR assays using SYBR Green I dye and a single quantification
standard containing two EBV DNA targets, were developed for the detection and measurement of EBV DNA load
in a variety of clinical samples. These assays have application in the investigation of EBV-related illnesses in
immunocompromised individuals.
Background
Epstein-Barr virus (EBV) causes infectious mononucleo-
sis, an acute but self-limiting disease affecting children
and young adults. After primary infection, the virus per-
sists indefinitely in B-lymphocytes [1], only to reactivate
when cellular immunity is impaired. In immunocompro-
mised individuals, EBV-related disorders following virus
reactivation are associated with significant morbidity
and mortality [2]. Up to 15% of transplant recipients
develop post-transplant lymphoproliferative disease
(PTLD), a heterogeneous group of disorders charac-
terised by EBV transformation of lymphocytes [3,4].
Although uncommon, PTLD is aggressive and coupled
with high mortality rates of 50-80% [4]. Also related to
other diseases in immunosuppressed individuals, includ-
ing chronic active EBV, fatal infectious mononucleosis
(IM) and EBV-associated haemophagocytic syndrome
(EBVAHS) [5-7], EBV is linked to several malignancies
such as nasopharyngeal carcinoma (NPC) and Burkitt’s
lymphoma (BL) [5]. In HIV-infected individuals, EBV is
associated with diseases such as oral hairy leukoplakia
and AIDS-related non-Hodgkin’s lymphoma [5,8].
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tent [9], EBV DNA is found in greater concentrations in
immunosuppressed populations [10-13]. The presence of
circulating EBV DNA does not always correlate with
symptomatic infection, nor does it predict clinical disease
in immunocompetent or immunosuppressed individuals
[2,9]. Nevertheless, although the correlation between
EBV burden and disease status is incompletely under-
stood, several studies have shown an association between
symptomatic infection and elevated DNA loads in clinical
samples [14,15]. Increasing virus burden is also believed
to be a rapid indicator of immunopathological changes
preceding and/or underlying the B-lymphocyte driven
changes caused by EBV [16]. Therefore, determining
EBV DNA loads in EBV-related disorders in immuno-
compromised populations is an important step towards
disease diagnosis, management and treatment [17].
Several methods for quantifying absolute DNA load have
been developed since its first application to EBV diagnos-
tics in 1999 [18-20]. These include semi-quantitative,
quantitative competitive and real-time PCR methods [21],
with each using different means for amplicon detection;
visualisation on agarose gel, Southern blot analysis and
enzyme immunoassay [21]. Real-time PCR quantification
is generally preferred for its wider dynamic range, speed,
ease of handling, sensitivity and specificity [2,22-25].
Although commercial assays incorporating probe-based
chemistries are available [26,27], in-house methods
employing high saturating dyes such as SYBR Green I are
more cost-effective and just as sensitive as the widely used
TaqMan PCR [21,28-30].
Here, in an effort to ascertain the relationship between
EBV DNA load and disease, two real-time quantitative
PCR (QPCR) assays using SYBR Green I dye and a sin-
gle quantification standard incorporating two separate
EBV genes, Epstein-Barr nuclear antigen-1 (EBNA-1)
and BamHI fragment H rightward open reading frame-1
(BHRF-1), were developed. EBV DNA was measured in
a range of clinical samples, including unfractionated
whole blood, plasma, PBMC and CSF from patients with
EBV-associated disorders or immune dysfunctions. EBV
sero-status was also determined for individuals in a
population sample to assess the correlation between
DNA load and antibody titres.
Methods
Groups with EBV-associated diseases or immune
disorders
A total of 60 clinical samples from 25 individuals with
various EBV-associated diseases or immune disorders
were collected between February 2007 and September
2008. Specimen types included EDTA whole blood,
plasma, PBMC and CSF. Each patient was assigned a
letter (A to Y) and classified into one of four groups.
Group 1 consisted of five patients with EBV-related
PTLD following matched-unrelated donor haematopoie-
tic stem cell transplantation, generating 40 samples:
whole blood (n = 20), plasma (n = 18) and CSF (n = 2).
Group 2 consisted of seven patients with IM, with
plasma (n = 4) or whole blood (n = 3) samples and
Group 3 was based on a single patient with EBVAHS
from whom a whole blood sample was available. Group
4 consisted of PBMC (n = 3) and plasma (n = 9) sam-
ples from 12 HIV-infected individuals with HIV RNA
plasma loads greater than 10,000 copies/ml.
Population sample
A fifth group was comprised of 218 individuals from a
population sample for whom whole blood and serum
were collected between 2004 and 2007. This included
46 males and 172 females with a mean age of 39
(SD = 10) and 40 (SD = 9.5) years respectively. These
individuals resided in one of four regions in eastern
Australia including Brisbane (n = 78), Newcastle
(n = 28), Geelong and the western districts of Victoria
(n = 45) and Tasmania (n = 67) [31].
Serology testing
EBV-specific antibody detection in the population sample
Quantitative EBV-specific serology was performed on
sera from individuals in Group 5 only. EBV VCA IgG
antibodies titres were determined by an immunofluores-
cence assay (IFA) using FITC conjugated anti-human
IgG prepared in goats (Sigma-Aldrich, Castle Hill, NSW,
Australia). Cells from the B95-8 marmoset cell line pro-
ductively infected with EBV were grown in 27 mls of
RPMI 1640-modified (ThermoFisher Scientific, Scoresby,
VIC, Australia) +10% foetal calf serum (FCS) (Thermo-
Fisher Scientific, Scoresby, VIC, Australia) medium
containing 3 mls of 0.4 mM phosphonoacetic acid
(Sigma-Aldrich, Castle Hill, NSW, Australia). Cells were
spotted on 10 well slides (Pathech, Preston, VIC, Austra-
lia) and used as the antigen. Four-fold dilutions of known
EBV positive sera were used as controls. Samples were
diluted using phosphate buffered saline containing 10%
FCS four-fold from 1:10 to an endpoint; samples with a
titre < 1:10 were reported as negative, whilst titres equal
to or greater than 1:10 were defined as positive.
Molecular testing
EBV gene targets, beta-globin and PCR controls
To maximise detection rates and reduce false negative
results, two primer sets targeting the highly conserved
EBV regions, EBNA-1 and BHRF-1, were used for PCR
amplification (Table 1). EBNA-1 is a latent protein
required for replication and genome maintenance and is
the only viral protein consistently expressed in EBV-
infected cells [32,33]. BHRF-1 is expressed in lytic
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Bcl-2 for enhancing cell survival [34]. Groups 2-5 were
evaluated by both PCR targets, while inadequate sample
volume limited testing to EBNA-1 in Group 1. The
beta-globin gene targeting the TAL57 region was used
as a ‘house-keeping’ gene to control for PCR inhibitors
and check for DNA integrity [35]. All samples were sub-
jected to beta-globin PCR prior to EBV QPCR. Contam-
ination was monitored by the use of PCR-grade water
and no template DNA controls.
DNA extraction and molecular assay design
DNA was isolated from 200 μlo fE D T Aw h o l eb l o o d ,
plasma or CSF using the GenElute™ Mammalian Genomic
DNA Miniprep Kit® (Sigma-Aldrich, Caste Hill, NSW
Australia) according to the manufacturer’s instructions,
a n de l u t e di n2 0 0μl elution buffer. The QIAamp DNA
mini kit (Qiagen, Doncaster, VIC, Australia) was used to
extract DNA from PBMC in accordance with the manu-
facturer’s instructions. Extracts were aliquoted in single
use volumes to prevent freeze-thaw cycles and stored at
-80°C prior to testing. Each reaction mixture was con-
tained in a PCR-certified colourless 200 μl flat capped
tube (Integrated Sciences, Willoughby, NSW, Australia) to
af i n a l2 5μl volume, comprising of 2.0 μl LightCycler® Fas-
tStart DNA Master SYBR Green 1 dye (Roche Diagnostics,
Castle Hill, NSW, Australia) at 10× concentration pre-
combined with the LightCycler® FastStart enzyme, 0.5 μl
of 0.2 mM sense and antisense primers (Invitrogen,
Mount Waverley, VIC, Australia), 0.8 μl of 25 mM MgCl2
and 5 μl of the DNA eluate. Samples were tested on the
36-well rotor on the Rotor-Gene 6000® analyser (Qiagen,
Doncaster, VIC, Australia). PCR was divided into two
cycles: a first cycle with three repeats at 40 seconds
for each stage, and a second cycle with 40 repeats at
30 seconds per stage. Thermal cycling conditions included
an optimised initial denaturation step followed by 95°C
denaturation, optimised annealing temperatures and
extension at 72°C (Table 1). To ensure complete product
formation, a final extensions t e pa t7 2 ° Cf o r5m i n u t e s
concluded the PCR. A melt analysis immediately followed
at between 60°C to 99°C as a check for amplicon purity.
For confirmation, EBNA-1 and BHRF-1 products were
electrophoresed in 2% agarose gel containing 1:20 dilution
of SYBR® safe DNA gel stain in 0.5× TBE buffer (Invitro-
gen, Mount Waverley, VIC, Australia).
Cloning of EBNA-1 and BHRF-1 DNA targets into plasmid
vector pGEM and standard curve construction
A novel feature of the assay was the design of a quantifica-
tion standard incorporating both EBNA-1 and BHRF-1
DNA targets in a single plasmid (Figure 1). This was done
to minimise the necessity for two separate EBV standards,
thus reducing costs and labour. The EBNA-1 and BHRF-1
DNA targets were linked using randomised primers
(Table 1) and inserted into the pGEM vector, using the
pGEM®-T Easy Vector System II (Promega Corporation,
Alexandria, NSW, Australia) according to the manufac-
turer’s instructions. The cloned targets were then purified
using the PureYield™ Plasmid MidiPrep System (Promega
Corporation, Alexandria, NSW, Australia), and stored in
single use aliquots. Target copy number was calculated
following double stranded DNA approximation using the
Beckman DU® 530 Life Science UV/Vis spectrophotometer
(Beckman Coulter, Gladesville, NSW, Australia). A new
plasmid aliquot was used for standard curve dilution for
Table 1 Oligonucleotides used for EBV QPCR, beta-globin detection, construction of plasmid and PCR thermal cycling
conditions
Target Primer
Name
Oligonucleotide Sequence
5’-3’
Amplicon
Length
GenBank
Accession
(position)
Reference Optimised PCR Thermal
Cycling Conditions
EBNA-1 QP1 GCC GGT GTG TTC GTA TAT GG 213 bp AJ507799
(97174-97386)
Stevens
et al, 1999
95°C initial denaturation for
10 mins; 58°C annealing
QP2 CAA AAC CTC AGC AAA TAT
ATG AG
BHRF-1 EA-1F GGA GAT ACT GTT AGC CCT G 208 bp AJ507799
(42105-42312)
Custom 98°C initial denaturation for
13 mins; 60°C annealing
EA-2R GTG TGT TAT AAA TCT GTT CCA
AG
Plasmid construct
(randomised primers in
bold)
EA-F CTA TAT GTC TGC TTA CTC
CGG CG /G GAG ATA CTG TTA
GCC CTG
554 bp N/A Custom 95°C initial denaturation for
10 mins; 55°C annealing
EB-R CGC CGG AGT AAG CAG ACA
TAT AG /CAA AAC CTC AGC
AAA TAT ATG AG
95°C initial denaturation for
10 mins; 55°C annealing
Beta-Globin TAL57 BG-1F TAG CAA CCT CAA ACA GAC
ACC A
247 bp EU760960
(171-417)
Custom 95°C initial denaturation for
10 mins; 61°C annealing
BG-1R CAG CCT AAG GGT GGG AAA AT
Abbreviations: EBNA-1, Epstein-Barr virus nuclear antigen-1; BHRF-1, BamHI fragment H rightward open reading frame-1; mins, minutes.
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1
to 10
6 copies/5 μl. PCR runs were accepted when the stan-
dard curve correlation co-efficient was ≥ 0.99.
Product identification, reproducibility, sensitivity, limit of
detection and specificity
PCR products were identified by an amplification curve,
melt analyses and amplification efficiency generated by the
Rotor-Gene™ 6000 Software 1.7 (Build 90). Positive EBV
DNA samples had a cycle threshold (CT) less than 40, and
melted between 86°C to 87°C with an average amplifica-
tion efficiency of 1.74. PCR products for EBNA-1 DNA
and BHRF-1 DNA were identified on agarose gel by 213
bp and 208 bp bands, respectively. Reproducibility studies
consisting of triplicates of each standard curve dilution
(10
1-10
5 copies/5 μl) were performed prior to testing.
Intra-assay variation was determined in three repeat assays
tested within 24 hours on three consecutive days. Inter-
assay variation was assessed using three different batches
of the same PCR master mix kit. Sensitivity was deter-
mined by end-point PCR using gel electrophoresis. To
establish the minimum DNA copy number that could be
reliably detected, ten plasmid replicates spanning 10
0 to
10
2 copies/5 μl were assayed in three separate runs. Primer
specificity was verified on the Basic Local Alignment
Search Tool on GenBank and by assaying known cytome-
galovirus (CMV), human herpesvirus 6 (HHV6), HIV and
varicella zoster (VZV) positive samples. The EBV QPCR
was evaluated against an external quality assurance pro-
gram (Quality Control for Medical Diagnostics (QCMD),
Glasgow, Scotland, http://www.qcmd.org/ for EBV QPCR
in 2008 and 2009.
Viral load calculation and result interpretation
Viral load calculations were based on DNA extraction
volume and final elution volumes as well as the number
of replicates tested. Samples were extracted and eluted
in equal quantities, keeping ratios constant. Hence, the
amount of sample used for PCR (5 μl) was multiplied by
a factor of 200 (elution volume) and divided by the
number of replicates to obtain a final measurement
expressed as DNA copies per millilitre (copies/ml) of
sample. This unit of measurement has close correlations
with copies per microgram of DNA, therefore does not
require normalisation to the amount of input DNA [36].
Furthermore, copies/ml removes unnecessary processing
steps and reduces costs, as well as minimising sample
volume for testing. EBV DNA was quantifiable in a
dynamic range spanning six logarithms with the mini-
mum reportable viral load at 2.0 × 10
2 copies/ml of
sample. Samples with no detectable target DNA were
assigned a load of zero and resulted as negative.
Statistical calculations
Data analysis was conducted with SPSS version 17.
Spearman’s (rho) correlation co-efficient was used to
assess the correlations between EBNA-1 and BHRF-1
DNA loads and VCA IgG antibody titres.
Results
Performance of EBV QPCR assays: reproducibility,
sensitivity, detection limit and specificity
The intra-assay and inter-assay co-efficient of variation
for EBNA-1 and BHRF-1 QPCRs are shown in Table 2.
Both EBV targets were detected at levels as low as 2.0 ×
10
2 copies/ml of sample. However, the reliable limit of
detection for both EBNA-1 and BHRF-1 DNA was 2.0 ×
10
3 copies/ml, where the proportion that were detected
(positivity ratio) were 97% and 93% respectively. Primers
showed no cross reactivity to other herpesviruses (data
not shown). All samples in both the 2008 and 2009
QCMD programs were correctly identified using the
EBNA-1 primers.
EBV detection and load in EBV-associated disease states
and immunocompromised individuals
Of the 60 samples from 25 immunocompromised
patients, 30 (50%) samples from 16 (64%) patients had
Figure 1 Plasmid vector pGEM showing location of cloned insert.
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was detected in 100%, 85.7%, 100% and 33.3% of
patients with PTLD, IM, EBVAHS and HIV-infected
individuals (Groups 1 to 4), respectively. EBV DNA
loads were detectable at ranges from 2.0 × 10
2 to 1.3 ×
10
8 copies/ml in these clinical samples, with the highest
EBV DNA load recorded in an individual with PTLD
(1.3 × 10
8 copies/ml of sample). High levels were also
seen in individuals with IM (2.0 × 10
5 copies/ml of
sample), EBVAHS (1.1 × 10
5 copies/ml whole blood),
and HIV infection (5.6 × 10
3 copies/ml of sample).
In Group 1 (PTLD), EBV DNA concentrations spanned
six logarithms and were detected in multiple samples from
early to end-stage disease. EBV DNA loads increased
sequentially following transplantation, decreased after
anti-viral therapy in Patients A and C and peaked ten days
prior to death in Patients A to D. EBV DNA loads were
detectable in some samples, but were absent in others. In
Patient D, plasma EBV DNA was qualitative PCR negative
Table 2 Intra- and inter-assay co-efficient of variation for EBNA-1 and BHRF-1 QPCRs
DNA Target
(copies/5 ul)
Mean CT Mean R-G 6000™ Results
(copies/5ul)
Standard Deviation of R-G 6000™ Results
(copies/5ul)
Mean % Variation COV
(%)
Mean R
2
EBNA-1 Intra-Assay Variation (same day)
100,000 18.03 87,329 6,670 12.68% 7.64 0.991
10,000 21.28 11,735 3,092 26.30% 26.34
1,000 25.21 1,057 100 7.00% 9.50
100 29.10 103 38 32.12% 37.25
10 32.91 11 6 46.16% 57.50
EBNA-1 Intra-Assay Variation (different days)
100,000 16.94 89,643 8,164 11.00% 9.11 0.998
10,000 20.31 10,678 1,207 10.00% 11.31
1,000 23.85 1,133 129 16.00% 11.41
100 27.65 102 4 3.00% 3.90
10 31.42 10 2 17.88% 18.95
BHRF-1 Intra-Assay Variation (same day)
100,000 17.23 97,884 9,144 8.08% 9.34 0.994
10,000 20.91 9,852 542 4.45% 5.50
1,000 24.38 1,146 202 16.12% 17.64
100 28.43 94 19 17.70% 20.51
10 31.95 11 5 35.38% 41.91
BHRF-1 Intra-Assay Variation (different days)
100,000 18.05 105,387 4,621 6.02% 4.38 0.997
10,000 21.75 9,779 818 6.23% 8.37
1,000 25.23 1,042 141 11.63% 13.55
100 29.06 89 18 13.76% 19.88
10 32.66 12 2 25.30 16.53
EBNA-1 Inter-Assay Variation
100,000 19.87 101,644 14,058 10.99% 28.35 0.990
10,000 23.75 10,660 1,471 13.65% 13.80
1,000 27.68 1,084 191 18.67% 17.60
100 31.71 111 49 33.58% 43.75
10 35.86 12 9 65.03% 75.85
BHRF-1 Inter-Assay Variation
100,000 17.30 109,065 14,266 10.01% 13.08 0.990
10,000 21.49 9,209 2,154 16.84% 23.39
1,000 25.49 860 251 22.19% 29.15
100 29.01 108 49 35.53% 45.33
10 32.29 15 8 69.41% 57.23
Abbreviations: CT, cycle threshold; Mean % variation, average percentage variation between the calculated (Rotor-Gene results) and the given concentration
(DNA target); COV, co-efficient of variation is the ratio of standard deviation to the mean; R
2-value, square root of the correlation co-efficient - in quantitation
PCR describes the percentage of the data which matches the hypothesis that the standards conform to a line of best fit.
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Group Patient
ID
Sex/Age Condition Specimen
(Positive/n Tested)
Target Detectable EBV DNA
Load (copies/ml)
Clinical Notes
1. A. M/46y PTLD Plasma (5/6) EBNA-1 Day +32 - 8.0 × 10
2 MUD HSCT for AML; EBV VCA IgG positive
pre-Tx; Plasma collected on Days +32, +39,
+46, +60, +75 and +81 for EBV QPCR; Plasma
EBV (qualitative) PCR positive on Days +75,
+78 and +81; Treatment with Foscarnet and
Rituximab after Day +75; Died of pneumonia
on Day +88
Day +46 - 1.0 × 10
3
Day +60 - 8.8 × 10
3
Day +75 - 1.1 × 10
6
Day +81 - 2.3 × 10
5
CSF (2/2) EBNA-1 Day +75 - 1.3 × 10
6 CSF collected on Days +75 and +78
Day +78 - 2.7 × 10
6
B. M/42y PTLD Whole Blood (1/5) EBNA-1 Day +95 - 2.0 × 10
7 MUD HSCT for AML; Plasma EBV (qualitative)
PCR positive Day +96; Plasma collected on
Day +95 for EBV QPCR; Died on Day +99
due to multi-organ failure
C. F/59y PTLD Plasma (3/6) EBNA-1 Day +45 - 2.2 × 10
5 MUD HSCT for AML; CMV reactivation on Day
+44, Treatment with Foscarnet and
ganciclovir on Day +52; Plasma collected
Days +38, +40, +45, +52 and +59; Died on
Day +66; EBV VCA IgG positive, HHV6 IgG
positive and CMV IgG positive pre-Tx
Day +52 - 9.6 × 10
3
Day +59 - 3.0 × 10
5
Whole Blood (1/8) EBNA-1 Day +46 - 6.6 × 10
4 EDTA collected Days +3, +5, +10, +17, +26,
+31, +33, +46
D. M/48y PTLD Plasma (4/6) EBNA-1 Day +40 - 3.4 × 10
3 MUD HSCT for AML; EBV VCA IgG positive
pre-Tx; Plasma collected Days +28, +33, +40,
+47, +54, +61; Plasma EBV (qualitative) PCR
negative on Day +62; Died Day +72 of multi-
organ failure
Day +47 - 3.6 × 10
4
Day +54 - 3.4 × 10
6
Day +61 - 6.3 × 10
6
Whole Blood (2/2) EBNA-1 Day +62 - 1.3 × 10
8 EDTA collected Days +62 and +63.
Day +63 - 1.8 × 10
7
E. F/57y PTLD Whole Blood (1/5) EBNA-1 9.5 × 10
4 No serology results available however clinical
notes indicate EBV reactivation; Plasma EBV
(qualitative) PCR positive 9-16 days after VL
testing done; negative at 1-7 months
thereafter.
2. F. Unknown IM Plasma (1/1) EBNA-1 3.7 × 10
4 EBV VCA IgM positive
BHRF-1 1.6 × 10
4
G. Unknown IM Plasma (0/1) EBNA-1 0 EBV VCA IgM positive
BHRF-1 0
H. Unknown IM Plasma (1/1) EBNA-1 7.6 × 10
3 EBV VCA IgM positive
BHRF-1 1.5 × 10
3
I. Unknown IM Plasma (1/1) EBNA-1 2.3 × 10
3 EBV VCA IgM positive
BHRF-1 8.7 × 10
4
J. M/17y IM Whole Blood (1/1) EBNA-1 1.0 × 10
5 EBV VCA IgM positive
BHRF-1 1.8 × 10
3
K. F/19y IM Whole Blood (1/1) EBNA-1 2.2 10
3 EBV VCA IgM positive
BHRF-1 5.6 × 10
4
L. F/53y IM Whole Blood (1/1) EBNA-1 2.0 × 10
5 EBV VCA IgM positive; acute glandular fever
BHRF-1 1.8 × 10
4
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blood. EBV-specific serology results were available for four
patients, and confirmed EBV infection prior to the trans-
plant. Four patients died as a result of PTLD complica-
tions, on average +81.25 days post transplantation. In
Group 2 (IM), EBV DNA was quantifiable from 1.5 × 10
3
to 2.0 × 10
5 copies/ml. One sample was negative for EBV
DNA (Patient G), despite a positive EBV VCA IgM profile.
Group 3 (EBVAHS) EBV DNA load results were similar to
Group 2, however Patient M died as a consequence of the
disease condition. In Group 4 (HIV), EBV DNA was
detectable in both plasma and PBMC ranging from 2.0 ×
10
2 to 5.6 × 10
3 copies/ml. However, 50% of these samples
were below 2.0 × 10
3 copies/ml.
EBV detection and load in the population sample
EBNA-1 and BHRF-1 DNA were detected in 11.0% and
21.6% of Group 5 (the population sample), respectively;
22.5% of samples were positive for at least one EBV
DNA target (Table 4). Of the 24 EBNA-1 DNA positive
samples, 91.7% were also BHRF-1 DNA positive, and of
the 47 BHRF-1 DNA positive samples, 46.8% were also
EBNA-1 DNA positive. Viral loads (combined targets)
were detectable between 2.0 × 10
2 to 6.2 × 10
4 copies/
ml of whole blood, but 54.2% and 85.1% of samples
were below 2.0 × 10
3 copies/ml for EBNA-1 and BHRF-
1 DNA levels, respectively. All samples with measurable
EBV DNA were EBV VCA IgG antibody positive, which
were found in 95.9% of the population sample. There
was a modest correlation between VCA IgG antibody
titres and BHRF-1 DNA load (Spearman’sr h o=0 . 1 3 ,
p = 0.05) and a weaker (not statistically significant) cor-
relation between EBNA-1 DNA load and VCA IgG anti-
body titres (Spearman’s rho = 0.11, p = 0.11) (Table 4).
Discussion
With increasing availability of nucleic acid testing
(NAT) methods, measuring EBV DNA in blood has pro-
v e nv a l u a b l ei nd i a g n o s i n ga n dm o n i t o r i n gP T L D
[16,21,22,37-41], NPC [42,43], IM [13,44], EBV infection
in HIV-infected individuals [8,13,45], BL [13] and
chronic active EBV infection [18,46]. In this study, we
Table 3: EBV DNA loads in various EBV-associated disease states and immunocompromised individuals (Continued)
3. M. M/36y EBVAHS Whole Blood (1/1) EBNA-1 7.5 × 10
4 EBV (qualitative) PCR positive; died of EBVAHS
BHRF-1 1.1 × 10
5
4. N. Unknown HIV Plasma (1/1) EBNA-1 0 HIV plasma VL 324, 000 RNA copies/ml
BHRF-1 1.0 × 10
3
O. Unknown HIV Plasma (0/1) EBNA-1, 0 HIV plasma VL 13, 000 RNA copies/ml
BHRF-1 0
P. Unknown HIV Plasma (0/1) EBNA-1, 0 HIV plasma VL 26, 800 RNA copies/ml
BHRF-1 0
Q. Unknown HIV Plasma (0/1) EBNA-1, 0 HIV plasma VL 21, 300 RNA copies/ml
BHRF-1 0
R. Unknown HIV Plasma (0/1) EBNA-1, 0 HIV plasma VL 12, 700 RNA copies/ml
BHRF-1 0
S. Unknown HIV Plasma (0/1) EBNA-1, 0 HIV plasma VL 1, 040, 000 RNA copies/ml
BHRF-1 0
T. Unknown HIV Plasma (0/1) EBNA-1, 0 HIV plasma VL 17, 700 RNA copies/ml
BHRF-1 0
U. Unknown HIV Plasma (0/1) EBNA-1, 0 HIV plasma VL 47, 500 RNA copies/ml
BHRF-1 0
V. Unknown HIV Plasma (1/1) EBNA-1 5.6 × 10
3 HIV plasma VL 16, 400 RNA copies/ml
BHRF-1 3.0 × 10
3
W. Unknown HIV PBMC (1/1) EBNA-1 < 2.0 × 10
2 HIV PBMC VL 12, 800 RNA copies/ml
BHRF-1 < 2.0 × 10
2
X. Unknown HIV PBMC (1/1) EBNA-1 < 2.0 × 10
2 HIV PBMC VL 12, 700 RNA copies/ml
BHRF-1 0
Y. Unknown HIV PBMC (0/1) EBNA-1, 0 HIV PBMC VL 118, 000 RNA copies/ml
BHRF-1
Abbreviations: Y, years; Group 1 (PTLD), post-transplant lymphoproliferative disease; Group 2 (IM), infectious mononucleosis; Group 3 (EBVAHS), Epstein-Barr virus
associated-haemophagocytic syndrome; Group 4 (HIV infection), human immunodeficiency virus; EDTA, ethylenediaminetetraacetic acid; CSF, cerebrospinal fluid;
PBMC, peripheral blood mononuclear cells; EBNA-1, Epstein-Barr virus nuclear antigen-1; BHRF-1, BamHI fragment H rightward open reading frame-1; ml,
millilitres; Bold lettering indicates Day QPCR positive post-transplant; AML, acute myeloid leukaemia; MUD; matched unrelated donor; HSCT, haematopoietic stem
cell transplantation; CMV, cytomegalovirus; VCA, viral capsid antigen; Ig, immunoglobulins; EA-D, early antigen-diffuse; EA-R, early antigen-restricted; VL, viral load.
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incorporating a novel single quantification standard con-
taining two EBV DNA targets for measuring viral load
on the Rotor-Gene 6000™. Substituting SYBR Green I
dye as a fluorescent marker for product accumulation
over fluorogenic probes, this method proved useful for
quantifying EBV DNA concentrations in clinical samples
from individuals with a variety of EBV-associated disor-
ders or immune dysfunctions and in a healthy popula-
tion sample.
Previous studies in PTLD have found that EBV DNA
loads increased with disease progression and decreased
with remission of lymphoproliferation [47,48]. This pat-
tern was observed in Group 1, where EBV DNA loads
appeared to be correlated with disease status. We found
similar EBV DNA loads to those previously reported,
with most studies showing EBV DNA concentrations
ranging from 5.0 × 10
2 to 2.0 × 10
7 copies/ml in whole
blood, plasma and serum [37,49,50]. EBV DNA was also
detected in CSF at concentrations comparable to plasma,
however detectable CSF EBV DNA has been previously
reported only in association with acquired immunodefi-
ciency syndrome (AIDS)-related brain lymphoma [51].
The significance of EBV DNA in CSF of PTLD remains
to be elucidated.
EBV DNA loads in IM patients were also similar to
those reported in the literature [13,22,26,44,52], although
some authors described loads as high as 10
6 and 10
7
copies/ml [12,46,53]. In Group 3, EBV DNA loads were
consistent with acute phase EBVAHS [46,54], and corre-
lated with the deterioration of the patient’s disease condi-
t i o n .E l a z a r ye ta la l s of o u n dt h a tav i r a ll o a dr a n g i n g
from 10
4-10
5 copies/ml was associated with poor patient
outcome [54]. One study found much higher EBV DNA
loads (up to 10
7 copies/ml) [55], but this may have been
due to differences in sample type and detection methods.
In Group 4, EBV DNA was detected in 33% of samples
(22% of plasma, 67% of PBMC), compared to 34% to 76%
positivity reported in other studies [8,26]. Notably how-
ever, these studies used whole blood for quantifying EBV
DNA load, which could have increased the probability of
viral DNA detection. As none of the Group 4 patients
were known to have EBV-related disease, low positivity
ratios and viral loads were expected.
Similar to our findings, the literature describes EBV
DNA detectable from 10
2 to 10
4 copies/ml and positiv-
ity ratios up to 29% in whole blood of healthy indivi-
duals [11-13,26,38,56-59]. However, DNA loads as high
as 5.5 × 10
5 copies/ml of whole blood and a positivity
ratio of 72% have been reported [58]. Differences in the
results may be attributable to more sensitive methods
associated with nested PCR and dual-labelled probes
[58]. Interestingly, another study showed 100% EBV
DNA positivity in whole blood, although DNA loads
were all below the detection limit of the assay
(2.0 × 10
3 copies/ml) [38].
In the population sample the EBV VCA IgG antibody
detection rate was consistent with levels of EBV sero-posi-
tivity in Western societies [2]. One study previously showed
a correlation between EBV VCA IgG antibody titres and
EBV viral load (detectable versus non-detectable) [60]. We
similarly found a modest correlation with quantitative
BHRF-1 DNA loads, and a weaker (not statistically signifi-
cant) correlation with EBNA-1 DNA load (see Table 4).
We noted some discrepancies in our measures of EBV
positivity. In one PTLD patient (Patient D), plasma was
qualitative EBV PCR negative whilst simultaneously
reporting an EBV DNA load of 1.3 × 10
8 copies/ml in
whole blood. However, a growing number of studies
have shown that cell-associated EBV is detectable before
plasma EBV DNA and can persist without accompany-
ing plasma DNA loads [21,48]. In Group 2, Patient G,
despite being EBV VCA IgM antibody positive, was EBV
QPCR negative. As EBV DNA loads can change rapidly
Table 4 EBV DNA load and antibody titre detection rates in the population samples (Group 5, n = 218)
Target Positive
n (%)
Detectable Range Spearman correlation (p)
EBNA-1 DNA
load
BHRF-1 DNA
load
Combined EBV Targets
DNA load
VCA
IgG
EBV EBNA-1 DNA load
(copies/ml)
24 (11.0%) 2.0 × 10
2 - 9.1 × 10
4 1.00
EBV BHRF-1 DNA load
(copies/ml)
47 (21.6%) 2.0 × 10
2 - 3.3 × 10
4 0.63
p < 0.001
1.00
Combined EBV targets DNA
load
(mean of BHRF & EBNA loads
where both
positive) (copies/ml)
49 (22.5%) 2.0 × 10
2 - 6.2 × 10
4 0.73
p < 0.001
0.97
p < 0.001
1.00
Viral capsid antigen IgG
(titres)
209 (95.9%) 1:10 - 1:5120 0.11
p = 0.11
0.13
p = 0.05
0.14
p = 0.04
1.00
Abbreviations: EBV, Epstein-barr virus; EBNA-1, Epstein-barr virus nuclear antigen-1; BHRF-1, BamHI fragment H rightward open reading frame-1; VCA, viral capsid
antigen; IgG, immunoglobulin G; Pos, positive.
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Page 8 of 11from being undetectable to being very high in a short
period of time [38], it is possible that sampling occurred
late in the convalescentp h a s ew h e r el o wE B VD N A
positivity ratios of 44% have been previously reported
[46]. Other factors contributing to DNA load variation
include differences in sample type, method of extraction
or NAT, and target chosen for PCR amplification.
As specimen type is known to influence DNA loads and
impact on assay performance [36], unfractionated EDTA
whole blood was used for DNA quantification where
possible. The dynamic changes of EBV DNA are better
reflected in circulating whole blood [38], which also
contains all the compartments that may harbour virus
[13,21,61]. However, despite reports of greater test sensi-
tivity with whole blood [12,36], EBV DNA load has
also been quantified in PBMC [14,16,62-64]. Although
infection is typically associated with cell compartments
[8,12,13], EBV DNA is also found in cell-free blood parti-
tions such as plasma or serum, usually in fragmented, cell-
derived form [12]. In this study, 2 of 9 plasma samples
from HIV-infected patients had detectable EBV DNA,
compared to 2 out of 3 PBMC samples. As we did not
have simultaneous plasma and PBMC samples from the
same individuals, we were unable to assess the differences
in viral load between these compartments. Further studies
comparing suitability of different sample types in various
EBV-related diseases and immune disorders are required.
The method of DNA purification is known to affect
viral load measurements. One study showed yield from
manually extracted DNA was 57% higher than that of
robotic systems [65]. Therefore, to improve DNA recov-
ery and maximise PCR sensitivity, samples here were
purified using a commercial silica-based column method
[61,66]. For optimal quantitation results, an earlier study
showed that DNA should be subjected to PCR within
one to two weeks post-extraction [67]. Here, delay
between extraction and testing could have contributed
to low DNA loads and positivity ratios in clinical sam-
ples. Furthermore, DNA from blood samples that had
undergone more than four freeze-thaw cycles were
found to be partially degraded [68]. Since the clinical
samples used here were tested retrospectively, monitor-
ing these conditions were not possible.
EBV DNA loads also vary according to type and size
of gene target [69]. Ryan et al, found assay sensitivity
was dependent on the specific gene segment and that
different targets had varying lower limits of detection
[15]. For EBV, BamHI-W is reportedly 10 times more
sensitive than other targets for PCR, allowing for detec-
tion of viral DNA at trace amounts [8,13,15]. However,
precise quantification of viral genomes is complicated by
the number of reiterated BamHI-W sequences among
EBV strains, which typically ranges between 7 and 11
repeats per genome [15]. To avoid overestimation in
this study, we chose to use the next most sensitive EBV
gene; EBNA-1 [15], and an abundantly expressed gene,
BHRF-1, for QPCR.
Despite targeting highly conserved EBV regions, selec-
tive drop out of amplifiable EBV DNA at the EBNA-1
and BHRF-1 loci was observed in Group 4 (Patients N
and X), and in 25 of 218 (11.5%) whole bloods from the
population sample. Instead of amplifying both EBV
DNA genes, only one target was detected, 93% of which
had viral loads less than 2.0 × 10
3 copies/ml. As beta-
globin was detected in all samples, PCR inhibitors and/
or defective nucleic acid purification methods were
excluded [70]. Alternatively, selective drop out may have
been due to low viral load and/or sampling error [71].
Since load determination is reliant on the amount of
EBV genomes pipetted into a reaction and assumes viral
homogeneity, QPCR results, particularly at low viral
load levels are prone to random sampling error. This
phenomenon is well documented in DNA quantification
and results in less reliable viral load measurements
[70,71]. Therefore, samples reporting low levels of target
nucleic acid may not be reproducible in repeated assays
from the same or different specimens [72].
Currently, there are no standardised methods for mea-
suring EBV DNA, complicating inter-laboratory compar-
isons in multicentre studies of EBV-related diseases.
Standardisation is difficult as PCR assay conditions vary
between laboratories, leading to variations in the accu-
racy and reproducibility of viral load quantification [21].
Although there appears to be a strong concordance
between laboratories for qualitative EBV DNA estimates,
there continues to be marked inconsistency in quantita-
tive results [73]. It has been suggested that the use of
unfractionated whole blood [26] or an international cali-
bration standard could be the first step towards standar-
disation [73]. However, instrumentation, chemistries,
gene targets and other test-related aspects remain
diverse. One solution for enabling inter-laboratory com-
parisons is the distribution of proficiency panels such as
QCMD. Such programs have already been used for
assessing methods for the detection and quantification
of EBV and other viruses [27,74,75].
Conclusion
This is the first reported study that uses the SYBR Green
I dye on the Rotor-gene 6000™ with a novel quantifica-
tion standard containing two EBV targets for measuring
EBV DNA load. The assays proved successful in the
quantification of EBV genomes in clinical cases and
should be considered as a cost effective and sensitive
PCR alternative to probe-based assays. This approach
can be modified to detect and quantify other latent
Lay et al. Virology Journal 2010, 7:252
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Page 9 of 11herpesviruses such as HHV6, CMV, and VZV. This pro-
cedure is suitable for robotics and automation, and
would be a useful addition in larger laboratories.
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